1. Midostaurin: a magic bullet that blocks mast cell expansion and activation. (30th August 2017) Authors: Valent, P.; Akin, C.; Hartmann, K.; George, T. I.; Sotlar, K.; Peter, B.; Gleixner, K. V.; Blatt, K.; Sperr, W. R.; Manley, P. W.; Hermine, O.; Kluin-Nelemans, H. C.; Arock, M.; Horny, H.-P.; Reiter, A.; Gotlib, J. Journal: Annals of oncology Issue: Volume 28:Number 10(2017) Page Start: 2367 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. High‐throughput screening of amino acid producing Corynebacterium glutamicum strains with accelerated LC‐MS/MS. Issue 9 (28th August 2020) Authors: Reiter, A.; Herbst, L.; Wiechert, W.; Oldiges, M. Journal: Chemie Ingenieur Technik Issue: Volume 92:Issue 9(2020) Page Start: 1337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Digitalization in industrial biotechnology – Challenges of miniaturization, automation, and interfaces. Issue 9 (28th August 2020) Authors: Hemmerich, J.; Osthege, M.; Reiter, A.; Wiechert, W.; Noack, S.; Oldiges, M.; Marquard, D.; Porr, M.; Lange, F.; Scheper, T.; Beutel, S.; von der Eichen, N.; Bromig, L.; Weuster-Botz, D. Journal: Chemie Ingenieur Technik Issue: Volume 92:Issue 9(2020) Page Start: 1160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE. (23rd June 2022) Authors: Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 904 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY. (23rd June 2022) Authors: Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 903 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES. (23rd June 2022) Authors: George, T.; Karner, K. H.; Moser, K. A.; Rets, A.; Reiter, A.; Radia, D. H.; Deininger, M.; Lin, H.-M.; Dimitrijević, S.; DeAngelo, D. J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 917 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA. (23rd June 2022) Authors: Stegelmann, F.; Jahn, E.; Koschmieder, S.; Heidel, F.; Hochhaus, A.; Hebart, H.; Isfort, S.; Reiter, A.; Bangerter, M.; Waller, C. F.; Wolleschak, D.; Scheid, C.; Göthert, J.; Schafhausen, P.; Kindler, T.; Radsak, M. P.; Gattermann, N.; Möhle, R.; von Bubnoff, N.; Schrade, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 945 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY. (23rd June 2022) Authors: Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 905 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Analysis of nucleophosmin–anaplastic lymphoma kinase (NPM‐ALK)‐reactive CD8+ T cell responses in children with NPM‐ALK+ anaplastic large cell lymphoma. (16th August 2016) Authors: K. Singh, V.; Werner, S.; Hackstein, H.; Lennerz, V.; Reiter, A.; Wölfel, T.; Damm‐Welk, C.; Woessmann, W. Journal: Clinical and experimental immunology Issue: Volume 186:Number 1(2016:Oct.) Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Oncostatin M is a FIP1L1/PDGFRA‐dependent mediator of cytokine production in chronic eosinophilic leukemia. Issue 6 (27th April 2013) Authors: Hoermann, G.; Cerny‐Reiterer, S.; Sadovnik, I.; Müllauer, L.; Bilban, M.; Gröger, M.; Horny, H.‐P.; Reiter, A.; Schmitt‐Graeff, A.; Mannhalter, C.; Valent, P.; Mayerhofer, M. Journal: Allergy Issue: Volume 68:Issue 6(2013:Jun.) Page Start: 713 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗